Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

Apoptotic cell death is important in the development and homeostasis of multicellular organisms
1 and is a highly controlled means of eliminating dangerous, damaged or unnecessary …

Tumour necrosis factor α (TNFα) is a critical inflammatory mediator in rheumatoid arthritis,
and may therefore be a useful target for specific immunotherapy. In support of this hypothesis, …

Objective To evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of multiple
infusions of a chimeric monoclonal anti‐tumor necrosis factor α antibody (cA2) (infliximab; …

Objective. Different sets of diagnostic criteria have been proposed for Sjögren's syndrome (SS),
but none have been validated with a large series of patients or in a multicenter study. We …

Objective. To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab
(anti–tumor necrosis factor [anti-TNF] monoclonal antibody) with those of MTX treatment …

Background Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have
shown efficacy in rheumatoid arthritis. This double-blind randomised trial compared …

Objective To investigate whether the established impaired phagocyte function in systemic
lupus erythematosus (SLE) patients also affects apoptotic cell clearance. Accumulation of …

Objective To investigate the efficacy and tolerability of infliximab therapy for the articular and
dermatologic manifestations of active psoriatic arthritis (PsA). Methods One hundred four …

Abstract Treatment with a chimeric mAb to TNF-α has been shown to suppress inflammation
and improve patient well-being in rheumatoid arthritis (RA), but the mechanisms of action of …